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g.2012.1Abstract Age-related macular degeneration (AMD) is a complex genetic disorder with multiple
etiologies. Multiple genes as well as environmental effects are thought to play a role in causing
AMD. Recent evidence pointed that elevated iron overload, resulting from hereditary defects of
iron homeostasis, is associated with retinal degeneration and consequently plays a role in the path-
ogenesis of AMD. Hemochromatosis is a genetic disorder in which excess iron is absorbed from the
diet and deposited in different tissues, primarily caused by mutations in HFE gene. Two major
mutations in HFE are responsible for most hemochromatosis cases, namely, C282Y and H63D.
In this work we gathered information relating to 37 AMD patients from Jordan, and investigated
the potential association between hemochromatosis, or more speciﬁcally, carrier state for a muta-
tion in HFE gene (which may moderately increase dietary iron absorption) and AMD, given the
effect of elevated iron levels on AMD occurrence. Questionnaires and blood samples were collected
from patients visiting the eye care clinic in the King Abdullah hospital in Jordan. DNA was
extracted from patient samples and mutations in HFE were genotyped (using polymerase chain
reaction (PCR), restriction fragment length polymorphism (RFLP), and DNA sequencing) and
compared to 106 control samples.
We could not detect C282Y (rs1800562) variant in our patient population or in the controls. For
carrier status with H63D (rs1799945) we had 30.3% compared to a frequency of 22.7% in theiotechnology and Genetics
ience and Technology, P.O.
962 77 6083419.
u.jo (A. Alkhateeb).
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0.008
178 A. Alkhateeb et al.controls (p= 0.37). H63D allele frequency was 15.2% in our patients compared to 11.8% in the
controls (p= 0.30).
H63D variant seems to be more frequent in AMD patients though not reaching a signiﬁcance of
p= 0.05. To date, this is the ﬁrst attempt to link HFE (particularly, H63D) mutation to AMD.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Retinal degeneration has been suggested recently to be pro-
moted by elevated iron levels [1]. Hereditary defects in iron
homeostasis that results in elevated retinal iron levels are sug-
gested to associate with retinal degeneration. These hereditary
defects include hemochromatosis, aceruloplasminemia, and
pantothenate kinase associated neurodegeneration (PKAN)
[2]. Age-related macular degeneration (AMD) has recently
been suggested to be caused (at least in some cases) by elevated
iron levels in the retina (which might be caused by one of the
hereditary defects of iron homeostasis) that leads to retinal
degeneration and, consequently, to AMD [2,3]. Suggested
involvement of iron in AMD by at least three lines of evidence;
elevated iron levels in retinas of AMD patients [4], develop-
ment of signs of macular degeneration in iron-overloaded ret-
inas of ceruloplasmin/hephaestin and hepcidin knockout mice
[5,6], and the development of early-onset drusen in an acerulo-
plasminemia patient with retinal iron overload [7].
The prevalence and mechanisms of iron overload in AMD
are not known. One probable cause of iron overload is a muta-
tion in HFE (the hereditary hemochromatosis gene). Pene-
trance of Hemochromatosis is relatively low, not every one
with HFE mutation would develop hemochromatosis, but
most often carriers of HFE mutations would result in a more
than normal absorption and consequent deposition of iron in
body tissues including the retina. Carriers of C282Y mutation
are high in the population and it reaches up to 10%. Here, we
describe a set of Jordanian Arab AMD patients and investi-
gate the frequency of C282Y and H63D variants in patients
and controls to examine whether HFE mutations play a role
in increasing the risk of AMD.
2. Subjects and methods
2.1. Subjects
A total of 143 individuals have participated in this study.
Thirty-seven patients with Age-related Macular Degeneration
(AMD) were recruited from the eye clinic in the King
Abdullah University Hospital in Irbid, Jordan. Average age
of patients was 71 years. Thirty percent (11/37) of patients
were females. Disease was diagnosed by one of the authors
(S.A.) using the AREDS staging system [8]. Optical coherence
tomography (OCT) and/or Fundus Fluorescein Angiography
(FFA) were done to conﬁrm diagnosis to all patients with
active disease. No investigations were done to end stage wet
AMD with macular scar or to patients with dry AMD with
small size drusens and very good visual acuity with no suspi-
cion of sub-retinal ﬂuid. Clinical and demographic data were
recorded for each patient. Controls were the attendants of
the hospital with no signs of eye problems or hemochromato-
sis. Positive control samples with homozygous mutant and
heterozygous mutants were kindly provided by Dr. OsamaSmadi (King Faisal hospital, Saudi Arabia) and Dr. Richard
Allen (University of Oklahoma Health Sciences Center,
USA). An informed consent was obtained from all participat-
ing individuals. This study was approved by the Institutional
Ethics Review Board of the Jordan University of Science
and Technology.
2.2. Genotyping
Peripheral blood samples were collected from all participants.
DNA was extracted using DNA puriﬁcation Kits (Qiagen).
Manufacturer’s protocol was followed. Two amplicons were
ampliﬁed by PCR for genotyping the three variants [9].
Primers were designed using primer3 software [10]. Sequences
for primers used to genotype C282Y were: forward 50-AAG-
GATAAGCAGCCAATGGA-30 and reverse 50-CCATAAT
TACCTCCTCAGGCACT-30 (GenBank Accession number
NT 007592.15). To genotype H63D primer set used was:
forward 50-GTTTGAAGCTTTGGGCTACG-30 and reverse
50-TACCCTTGCTGTGGTTGTGA-30 (GenBank Accession
number NT 007592.15). Ampliﬁcations were performed in a
total volume of 25 ll using the thermal cycler (icycler, Bio-
Rad). Each PCR reaction contained 12.5 ll GoTaq Green
Master mix, 2· (dNTPs, MgCl2, PCR buffer and Taq poly-
merase) (Promega), 2.5 ll of each primer (1 lM ﬁnal concen-
tration) (Alpha DNA), 4.5 ll nuclease free water, and 3.0 ll
(75 ng) of DNA template. After an initial step of 5 min at
95 C, the samples were processed through 35 temperature cy-
cles of 30 s at 94 C, 30 s at 56 C, and 30 s at 72 C, and a ﬁnal
extension step of 72 C for 10 min. PCR products were run on
2% agarose gel and visualized by UV light after ethidium bro-
mide staining to assess the correct sizing of the ampliﬁed prod-
uct. Following PCR, products were digested by RsaI for
C282Y and MboI for H63D (Fermentas). The restriction frag-
ments of PCR products were separated by electrophoresis on a
3% agarose gel containing 10 lg/ml ethidium bromide, and
visualized by UV light and genotypes recorded. Positive and
negative controls were included in each run. Direct sequencing
of PCR-ampliﬁed fragments was performed to conﬁrm the
RFLP detected variants. Sequencing was performed in both
directions (forward and reverse). The puriﬁcation of PCR
product and sequencing reaction were done by Macrogen
Company (Korea). The sequences were analyzed using Bioedit
software available online (http://www.mbio.ncsu.edu/bioedit/
bioedit.html).
2.3. Statistical analysis
Data were entered in excel for the calculation of allele and
genotype frequencies. Hardy–Weinberg equilibrium (HWE)
was tested to determine if the population was fulﬁlling the
HWE at each mutation locus. It was assessed in the observed
genotype distribution with a Chi square test. Allelic associa-
tion p-values were determined using a Chi square test in cases
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mined by the Freeman-Halton extension of Fisher’s exact test
for a 2 · 3 contingency table which evaluates the occurrence of
all three genotypes as an array between the cases and controls
[11]. A web-based calculator was used to compute p-values
(Vassar Stats). A p value <0.05 was considered to be statisti-
cally signiﬁcant for both tests. Using the Genetic Power Calcu-
lator (http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) we
found that we need 31 cases to get 80% power to detect allelic
association for H63D (assuming a relative risk of two for Aa
and six for AA genotypes, alpha = 0.1). Number of cases
needed to get 80% differs by the marker because markers have
different frequencies. C282Y was not present in our population
(patients and controls). Consequently, our sample size is en-
ough given the allele frequency of the marker.
3. Results
We had 37 AMD patients and 106 unaffected controls. Com-
plete clinical data were obtained for all AMD patients and
complete demographics were obtained from all participating
individuals. Genotyping was done for 33 patients (4 patients
did not provide blood samples) and all controls. Among
AMD patients 11 were females (30%) and 26 were males while
among controls there were 57 females (53%) and 49 males. For
patients, mean age was 71.6 ± 6.9 years, while for controls
mean age was 62.8 ± 7.9 years. Average age of diagnosis for
patients was 68.5 years. Dry AMD constituted 42% of
patients, wet AMD were 25%, and dry and wet AMD were
33%. Only 4 patients (11%) had a single eye involvement,
and the rest had bilateral AMD. Twelve AMD patients were
diabetic (32%). Twenty-six patients (70%) were receiving
Bevacizumab for treatment and 11 (30%) were not receiving
treatment.Figure 1 Gel electrophoresis for HFE SNP (H63D) PCR product and
negative control, Lane 2 (202 bp) PCR product, Lane 3 (99 + 59 +
(147 + 99 + 59 + 48 bp) represents RFLP product for heterozygo
homozygous CC.We genotyped patient and control samples using PCR of
the region continuing the variants followed by restriction en-
zyme digestion of the ampliﬁed product. Band patterns were
scored and samples genotyped (Fig. 1). We sequenced a subset
of data to conﬁrm our RFLP results (Fig. 2). We could not de-
tect C282Y variant in our patients or in the controls. Geno-
typic and allelic frequencies of patients and controls for
H63D are summarized in Tables 1 and 2, respectively. Geno-
typic frequencies met HWE expectations. We could not detect
association between H63D genotypes (p= 0.37) and alleles
(p= 0.30) with AMD phenotype.
4. Discussion
This is the ﬁrst paper to discuss AMD disease in Jordan, and
the ﬁrst, to the best of our knowledge, to assess the contribu-
tion of H63D variant in HFE gene to AMD. Iron is an impor-
tant cofactor in multiple proteins and enzymes that are
involved in cellular metabolic functions including DNA repli-
cation, membrane biogenesis, oxygen transport, and respira-
tory chain electron transfer. AMD patients have iron
metabolism abnormalities which may aggravate oxidative ret-
inal injury [12]. While the probability that iron accumulation is
simply a result of as opposed to a cause to AMD might not be
an invalid idea, much evidence points to a more or less direct
role in AMD pathogenesis.
H63D has an established role in iron homeostasis [13].
H63D also affects transferrin saturation levels [14], and hetero-
zyotes for H63D showed a signiﬁcant increase in transferrin
saturation and serum ferritin levels as compared to HFE wild
type controls [15–17]. HFE H63D mutation frequency shows
high variability worldwide [18]. It ranges from 23.0% in Bul-
garia [19] to 3.5% in Ecuador [20]. Allelic frequency of
H63D in Jordan is 11.25% [18].its RFLP products. Lane L represents 50 bp DNA ladder, Lane 1
48 bp) represents RFLP product for homozygous GG, Lane 4
us CG, Lane 5 (147 + 59 bp) represents RFLP product for
Figure 2 Sequencing electropherogram of HFE SNP (H63D),
vertical arrow points to the rs1799945 polymorphism.
Table 1 Genotype distributions of HFE H63D variant in
AMD patients and controls.
Genotype AMD patients (%) Controls (%) p-valuea
GG 23 (69.7) 83 (78.3) 0.37
GC 10 (30.3) 21 (19.8)
CC 0 (0) 2 (1.9)
Total 33 106
a Genotypic association p-values were calculated using an exten-
sion of Fisher’s exact test for a 2 · 3 contingency table.
180 A. Alkhateeb et al.In our study we could not detect any difference in the dis-
tribution of H63D alleles in AMD patients as compared to
controls, and thus, H63D mutation does not appear to play
a major role in increasing the risk of AMD. Consequently,
the potential involvement of iron in modulating oxidative in-
jury in AMD might be not related to different functions of
H63D and wild type alleles.
Various factors could be taken into account with respect to
these results. H63D is less penetrant than C282Y mutation and
thus an effect of C282Y on increasing the risk of AMD is pos-
sible. C282Y is so rare in the Jordanian population; we de-
tected none in our patients or in our controls. In a recent
study Asleh et al. could not ﬁnd association between AMD
and C282Y due to the low frequency of the allele in the same
region [21]. It is possible that H63D alleles increase the risk of
AMD in a small number of cases and its effect is minor, thus
such an effect might not be detectable in this study. The small
number of patient samples might also contribute to a lower
power to detect this minor effect. Finally, environmental fac-
tors might play a role in exacerbating or modulating the effect
of H63D mutation on AMD risk, such potential factors were
not analyzed in this study.
In conclusion, we analyzed the association of two hemo-
chromatosis HFE mutations; C282Y, and H63D in AMD pa-
tients. C282Y, the major hemochromatosis causing mutationTable 2 Allele distributions of HFE H63D variant in AMD patien
Allele AMD patients (%) Controls (%
G 56 (84.8) 187 (88.2)
C 10 (15.2) 25 (11.8)
Total 66 212
a Allelic association p-values were calculated using a Chi square test.was completely absent from our AMD patients and controls.
This is consistent with the fact that hemochromatosis has a
very low prevalence in Jordan and that it is not merely un-
der-diagnosed. H63D mutation was found to be common with
11.7% allele frequency, but it plays a minor role in hemochro-
matosis as compared to C282Y mutation. We analyzed the
association of H63D mutation with the risk of developing
AMD but we could not detect such association in our test
group suggesting that this mutation does not play a major role
in increasing the risk of developing AMD in Jordanian Arab
population.
Brief summary statement
We describe the clinical characteristics of a sample of AMD
patients from Jordan and assess the contribution of HFE gene
variants C282Y and H63D in increasing the risk of AMD by
an association analysis.Acknowledgments
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